The goals of the Tjssue Bank Core are to aid SPORE investigators: 1) to identify tumor biologic and molecular genetic correlates of diagnosis, prognosis, response, progression, and survival in the context of the SPORE related investigations;2) to maintain a searchable database of clinical and laboratory data for use by SPORE investigators;and 3) to provide a resource for banked specimens for future studies. Core Laboratory functions are designed to increase the power of the individual projects to detect biologic differences among patients entering the SPORE studies and identify molecular correlates of response versus resistance, and to be flexible enough to address individual investigator needs. In the previous funding period, the tissue core was located at the well established Mayo Clinic Myeloma Core facilities which received, processed, stored, archived and distributed clinically annotated cellular (bone marrow and PB cells) and molecular (DMA and RNA) and serum samples to investigators participating in this SPORE. Samples from the SPORE have been collected, tested, and archived separately from other Core resources, such as the ECOG or the Mayo Program Project reference laboratories;however, these resources have been shared between these cores resources, thereby increasing the pool of samples available for correlative science by the SPORE investigators. Due to the increased needs of our growing SPORE and in close cooperation and collaboration with the core at the Mayo clinic, we have now established a tissue core facility at the Dana Farber Cancer Institute. To make efforts at the Mayo Clinic and at the DFCI seamless and compatible for annotated sample sharing, we have utilized the same standard operating procedures for bone marrow processing, myeloma cell purification, and cryopreservation. Our biostatical and clinical data management at both the institutions are integrated in Core 3, which allows sharing of data and compatibility in sample selection for research studies. This Core provides an independent, current, and quickly searchable database of clinical and laboratory results and archived biospecimens. Data forms completed at the time of collection of the samples are entered into a common clinical, laboratory, and archival database. Follow up data is obtained and entered as required. All data are then stored in a common database accessible by the Statistics center. All patients have measurement of key biological variables requested by SPORE investigators. Unused specimen including sorted cells, DNA, RNA and cytospin slides are stored for future use on all patients. Subsequent use of banked samples beyond that specified in this SPORE proposal will be provided only with agreement from SPORE Director and the SPORE Principal Investigators. This Core is lead by Drs. Fonseca and Munshi, who are experienced in managing Core laboratories in a multi-institutional cooperative setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100707-07
Application #
7917457
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
7
Fiscal Year
2009
Total Cost
$174,767
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ye, Shuai; Lawlor, Matthew A; Rivera-Reyes, Adrian et al. (2018) YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res 78:2705-2720
Hunter, Zachary R; Xu, Lian; Tsakmaklis, Nickolas et al. (2018) Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv 2:2937-2946
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Michallet, M; Chapuis-Cellier, C; Dejoie, T et al. (2018) Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 32:376-382
Ray, A; Das, D S; Song, Y et al. (2018) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia 32:843-846

Showing the most recent 10 out of 407 publications